Celtic Therapeutics Management L.L.L.P. (Celtic Therapeutics) has announced a name change to Auven Therapeutics Management L.L.L.P (Auven Therapeutics) effective from March 11, 2013.
The name change was made in order to overcome confusion related to other Celtic entities, which are not part of Auven Therapeutics.
Auven Therapeutics’ rebrand reflects the Company’s mission to provide the gold (Au) standard in drug (Ven) development, progressing promising therapeutic pharmaceutical candidates in areas of unmet medical need.
Auven Therapeutics was founded by Dr. Peter B. Corr and Stephen Evans-Freke in 2007 and is pursuing an innovative investment strategy - while it is structured as a private equity fund, it also operates as a drug development company.
Commenting on the new name and the strategy of the fund, co-founder and co-Managing General Partner Stephen Evans-Freke said: “Capitalizing on the wealth of expertise of our development team, we take ownership and control of the development of carefully selected clinical-stage therapeutic assets in order to build value around them to the point where they are attractive acquisition opportunities for established pharmaceutical and biotechnology companies.”
Auven Therapeutics has a portfolio of biologic and small molecule therapeutic candidates, primarily comprising preclinical to mid-stage development programs, for a wide range of therapeutic indications including cancer, ophthalmic conditions, women’s health and orphan diseases.
It has ownership of or a majority interest in the therapeutic assets of ADC Therapeutics, Spirogen, Resolvyx and Kiacta, and a minority investment in Kolltan and Sprout Pharmaceuticals.
Dr. Peter B. Corr, co-founder and co-Managing General Partner added: “We are excited about our portfolio of innovative therapeutic assets. In particular, our investments in Spirogen and ADC Therapeutics have great potential to develop new and much more effective treatments for a variety of cancers.”